Is modulation of sodium-calcium exchange a therapeutic option in heart failure?
Gerd
G
Hasenfuss
Wolfgang
W
Schillinger
D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000502:physiology; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D012508:Sarcolemma / Q000187:drug effects / Q000378:metabolism; D019831:Sodium-Calcium Exchanger / Q000037:antagonists & inhibitors / Q000502:physiology*; D013890:Thiourea / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
C101670:2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate; D002317:Cardiovascular Agents; D010455:Peptides; D019831:Sodium-Calcium Exchanger; C066745:exchanger inhibitory peptide; D013890:Thiourea; D002118:Calcium